Yokohama, Japan

Kazunori Oba

This inventor holds 1 USPTO granted patent. Top assignee: Meiji Seika Kaisha, Ltd.. Active years: 1985.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kazunori Oba. Retrieved from https://idiyas.com/inventor/kazunori-oba

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 1985

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kazunori Oba: Innovator in Antiviral Agents

Introduction

Kazunori Oba is a notable inventor based in Yokohama, Japan. He has made significant contributions to the field of antiviral agents, showcasing his expertise and dedication to medical innovation. His work is particularly relevant in the ongoing fight against viral diseases.

Latest Patents

Kazunori Oba holds a patent for an antiviral agent that comprises as an active component a substance known as SF-2140. This invention includes a pharmaceutically acceptable carrier and outlines a method for treating viral diseases by administering a pharmaceutically effective amount of SF-2140. This patent reflects his commitment to developing effective treatments for viral infections.

Career Highlights

Oba is associated with Meiji Seika Kaisha, Ltd., a company known for its focus on pharmaceutical advancements. His role in this organization has allowed him to contribute to significant research and development efforts in the field of antiviral medications.

Collaborations

Kazunori Oba has worked alongside talented colleagues, including Tatsuo Ito and Harumi Fukuyasu. Their collaborative efforts have likely enhanced the research and development processes within their projects.

Conclusion

Kazunori Oba's innovative work in antiviral agents exemplifies the importance of research in combating viral diseases. His contributions, along with his collaborations, continue to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…